In Reply We would like to thank Zhang et al for their interest in our recent phase 1 nonrandomized controlled trial of chemoradiotherapy with concurrent pembrolizumab for the treatment of locally advanced non–small cell lung cancer (NSCLC)1 and are appreciative of their thoughtful inquiries regarding this work. We would like to address their points in order, as follows.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jabbour S, Simone CB, Malhotra J. Assessing Expression of PD-L1 in Tumor-Associated Macrophages—Reply. JAMA Oncol. 2020;6(10):1634–1635. doi:10.1001/jamaoncol.2020.2722
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: